Retatrutide versus Ozempic: trial data
Lilly reported new Phase 3 results on October 28, 2026 from TRANSCEND-T2D-2, comparing investigational retatrutide with Ozempic 2 mg in adults with type 2 diabetes. This is a direct comparison within one trial, which makes it more informative for that specific question than lining up percentages from unrelated studies. 1
What question did the trial ask?
The ClinicalTrials.gov record describes a randomized, open-label, parallel-group study in adults whose diabetes was inadequately controlled with metformin, with or without an SGLT2 inhibitor. Its primary outcome is change in HbA1c at week 80; body-weight changes are listed among the secondary outcomes. 2
That design identifies the population and comparison being tested. It does not automatically answer the same question in people without diabetes, with another semaglutide formulation or at a different follow-up time.
What did Lilly report?
Lilly's efficacy-estimand analysis reported the following average changes at 80 weeks. The company described detailed presentation and peer-reviewed publication as forthcoming in its announcement. 1
| Outcome | Retatrutide 9 mg study arm | Retatrutide 12 mg study arm | Ozempic 2 mg comparator |
|---|---|---|---|
| Body-weight change | −19.5% | −20.9% | −9.4% |
| HbA1c change | −2.2 percentage points | −2.2 percentage points | −1.8 percentage points |
| Discontinued because of adverse events | 4.8% | 7.9% | 2.7% |
Why do the analysis details matter?
An efficacy estimand asks about an outcome under specified treatment-adherence assumptions. It should be read with its definition, not treated as a prediction for every person who might begin a treatment. Lilly specifies that this analysis assumes participants remained on study intervention without certain additional glucose-lowering medication. 1
A practical reading method is to keep the endpoint, study population, time point and analysis approach next to every percentage. If one of those changes, the comparison changes too. The table describes trial arms; it is not a dosing guide.
Why are the registry and announcement numbers different?
The registry record available at this check, last posted September 28, retains estimated enrollment of 1,250 and an active-not-recruiting status. Lilly's later announcement describes 1,298 participants. These are differently dated records, so the older registry estimate should not silently replace the sponsor's reported enrollment. 1 2
The registry also distinguishes primary completion from overall study completion. That distinction helps explain how a main outcome can be announced while longer follow-up remains relevant. 2
What does this change about approval status?
Lilly's current retatrutide information still describes it as investigational and not an approved medicine. Trial results, regulatory submission and approval are separate milestones. 3
For ongoing reading, use the named trial report for its specific outcome and the broader comparison guide for receptor targets and differences between studies. Neither a clinical-trial result nor a shared ingredient name validates a research catalogue vial.
Scope for European readers
This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.